Inactive Instrument

Bone Medical Limited Share Price Australian S.E.

Equities

AU0000BNEDC4

Pharmaceuticals

End-of-day quote Australian S.E.
- AUD - Intraday chart for Bone Medical Limited

Financials

Sales 2024 * 800M 533M 42.13B Sales 2025 * 30.5B 20.34B 1,606B Capitalization 528M 352M 27.79B
Net income 2024 * -11.7B -7.8B -616B Net income 2025 * 9.3B 6.2B 490B EV / Sales 2024 * -11.3 x
Net cash position 2024 * 9.6B 6.4B 506B Net cash position 2025 * 2.3B 1.53B 121B EV / Sales 2025 * -0.06 x
P/E ratio 2024 *
-33.5 x
P/E ratio 2025 *
33.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.28%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 30/04/19
Chairman 65 19/05/19
Chief Tech/Sci/R&D Officer 68 28/02/21
Members of the board TitleAgeSince
Director/Board Member 54 20/02/19
Director/Board Member - 30/06/16
Chairman 65 19/05/19
More insiders
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
More about the company